Bringing IDH into the Fold

Gelareh Zadeh; Kenneth Aldape

doi:10.1016/j.ccell.2016.01.010

Bringing IDH into the Fold

Cancer Cell. 2016 Feb 8;29(2):139-40. doi: 10.1016/j.ccell.2016.01.010.

Authors

Gelareh Zadeh¹, Kenneth Aldape²

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; Division of Neurosurgery, University Health Network, Toronto, ON M5T 2S8, Canada. Electronic address: gelareh.zadeh@uhn.ca.
² Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON M5T 2S8, Canada.

PMID: 26859452
DOI: 10.1016/j.ccell.2016.01.010

Abstract

Glioma-associated mutations in IDH1 or IDH2 lead to aberrant DNA methylation. A recent paper shows that loss of methylation-sensitive CTCF binding in IDH mutant cells leads to disruption of enhancer boundary function, which results in aberrant activation of PDGFRA expression via an enhancer associated with an adjacent gene.

Publication types

Comment

MeSH terms

Gene Expression Regulation, Neoplastic*
Glioma / enzymology*
Glioma / genetics*
Humans
Insulator Elements / genetics*
Isocitrate Dehydrogenase / genetics*
Mutation / genetics*
Oncogenes / genetics*

Substances

Isocitrate Dehydrogenase